Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Linagliptin and Empagliflozine on Type 2 Diabetes Mellitus
IRCT20221016056201N1Phase 2Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of linagliptin and empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Arak University of Medical Sciences. Started Feb 2023; status: completed.
02
Drugs
linagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20221016056201N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221016056201N1.